An Open Label Phase Ib Dose-Escalation Study of TRC105 Combined with Standard-Dose Bevacizumab for Advanced Solid Tumors
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of this research study is to determine the safety of the TRC105 monoclonal antibody when given in combination with bevacizumab and how well you tolerate the combination.
Description
The purpose of this research study is to determine the safety of the TRC105 monoclonal antibody when given in combination with bevacizumab and how well you tolerate the combination.
Details
| Condition | Metastatic Cancer |
|---|---|
| Age | 18years - 100years |
| Clinical Study Identifier | TX2182 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.